Ines Rombach1, William Tillett2,3, Deepak Jadon4, Laura Tucker5, Marion Watson5, Anne Francis5, Yvonne Sinomati5, Lucy Eldridge1, Melina Dritsaki1, Susan J Dutton1, Hussein Al-Mossawi5, Nicola Gullick6, Ben Thompson7, Laura C Coates8. 1. Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. 2. Royal National Hospital for Rheumatic Diseases, Bath, UK. 3. Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. 4. Department of Medicine, University of Cambridge, Cambridge, UK. 5. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. 6. Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. 7. Department of Rheumatology, Musculoskeletal Unit, Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK. 8. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. laura.coates@ndorms.ox.ac.uk.
Abstract
BACKGROUND: The Tight Control of psoriatic arthritis (TICOPA) trial confirmed improved clinical outcomes with a treat to target (T2T) strategy in psoriatic arthritis (PsA). This consisted of 4-weekly review and escalation of 'step up' therapy (single disease modifying therapy (DMARD), combination DMARDs and then biologics) based on remission criteria. Based on this, a T2T approach is supported by European PsA treatment recommendations. However, it is not commonly implemented in routine care primarily due to feasibility and cost concerns. In the TICOPA trial, the same treatment regime was used for all participants regardless of their disease profile. Despite the recognition of PsA as a highly heterogeneous condition, no studies have tailored which drugs are used depending on disease severity. The cohort will establish real world outcomes for the T2T approach in PsA and also form the basis of a trials within cohorts (TWiCs) design to test alternative therapeutic approaches within embedded clinical trials providing an evidence base for treatment strategy in PsA. METHODS: The Multicentre Observational Initiative in Treat to target Outcomes in Psoriatic Arthritis (MONITOR-PsA) cohort will apply a T2T approach within routine care. It will recruit newly diagnosed adult patients with PsA starting systemic therapies. The cohort is observational allowing routine therapeutic care within NHS clinics but a T2T approach will be supported when monitoring treatment within the cohort. Eligible participants will be adults (≥18 years) with active PsA with ≥ 1 tender or swollen joints or enthesis who have not previously had treatment with DMARDs for articular disease. DISCUSSION: This study is the first TWiC designed to support a fully powered randomised drug trial. The results from the observational cohort will be compared with those observed in the TICOPA trial investigating the clinical effectiveness and health care costs of the pragmatic T2T approach. Nested trials will provide definitive RCT evidence establishing the optimal management of PsA within the T2T approach. The TWiCs design allows robust generalizability to routine healthcare, avoids disappointment bias, aids recruitment and in future will allow assessment of longer-term outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT03531073 . Retrospectively registered on 21 May 2018.
BACKGROUND: The Tight Control of psoriatic arthritis (TICOPA) trial confirmed improved clinical outcomes with a treat to target (T2T) strategy in psoriatic arthritis (PsA). This consisted of 4-weekly review and escalation of 'step up' therapy (single disease modifying therapy (DMARD), combination DMARDs and then biologics) based on remission criteria. Based on this, a T2T approach is supported by European PsA treatment recommendations. However, it is not commonly implemented in routine care primarily due to feasibility and cost concerns. In the TICOPA trial, the same treatment regime was used for all participants regardless of their disease profile. Despite the recognition of PsA as a highly heterogeneous condition, no studies have tailored which drugs are used depending on disease severity. The cohort will establish real world outcomes for the T2T approach in PsA and also form the basis of a trials within cohorts (TWiCs) design to test alternative therapeutic approaches within embedded clinical trials providing an evidence base for treatment strategy in PsA. METHODS: The Multicentre Observational Initiative in Treat to target Outcomes in Psoriatic Arthritis (MONITOR-PsA) cohort will apply a T2T approach within routine care. It will recruit newly diagnosed adult patients with PsA starting systemic therapies. The cohort is observational allowing routine therapeutic care within NHS clinics but a T2T approach will be supported when monitoring treatment within the cohort. Eligible participants will be adults (≥18 years) with active PsA with ≥ 1 tender or swollen joints or enthesis who have not previously had treatment with DMARDs for articular disease. DISCUSSION: This study is the first TWiC designed to support a fully powered randomised drug trial. The results from the observational cohort will be compared with those observed in the TICOPA trial investigating the clinical effectiveness and health care costs of the pragmatic T2T approach. Nested trials will provide definitive RCT evidence establishing the optimal management of PsA within the T2T approach. The TWiCs design allows robust generalizability to routine healthcare, avoids disappointment bias, aids recruitment and in future will allow assessment of longer-term outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT03531073 . Retrospectively registered on 21 May 2018.
Entities:
Keywords:
Cohort multiple RCT or cmRCT; Psoriatic arthritis; TWiCs; Treat-to-target; Trials within cohorts
Authors: M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden Journal: Lancet Date: 1997-08-02 Impact factor: 79.321
Authors: Axel Patrice Villani; Marie Rouzaud; Morgane Sevrain; Thomas Barnetche; Carle Paul; Marie-Aleth Richard; Marie Beylot-Barry; Laurent Misery; Pascal Joly; Michel Le Maitre; Selim Aractingi; François Aubin; Alain Cantagrel; Jean-Paul Ortonne; Denis Jullien Journal: J Am Acad Dermatol Date: 2015-06-06 Impact factor: 11.527
Authors: Laura C Coates; Anna R Moverley; Lucy McParland; Sarah Brown; Nuria Navarro-Coy; John L O'Dwyer; David M Meads; Paul Emery; Philip G Conaghan; Philip S Helliwell Journal: Lancet Date: 2015-10-01 Impact factor: 79.321
Authors: Ana-Maria Orbai; Maarten de Wit; Philip Mease; Judy A Shea; Laure Gossec; Ying Ying Leung; William Tillett; Musaab Elmamoun; Kristina Callis Duffin; Willemina Campbell; Robin Christensen; Laura Coates; Emma Dures; Lihi Eder; Oliver FitzGerald; Dafna Gladman; Niti Goel; Suzanne Dolwick Grieb; Sarah Hewlett; Pil Hoejgaard; Umut Kalyoncu; Chris Lindsay; Neil McHugh; Bev Shea; Ingrid Steinkoenig; Vibeke Strand; Alexis Ogdie Journal: Ann Rheum Dis Date: 2016-09-09 Impact factor: 19.103
Authors: Ines Rombach; Laura Tucker; William Tillett; Deepak Jadon; Marion Watson; Anne Francis; Yvonne Sinomati; Susan J Dutton; Laura C Coates Journal: Ther Adv Musculoskelet Dis Date: 2022-01-10 Impact factor: 3.625